Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- eculizumab
- Vaxchora (cholera vaccine, live)
Interactions between your drugs
eculizumab cholera vaccine, live
Applies to: eculizumab, Vaxchora (cholera vaccine, live)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.
MANAGEMENT: The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies. Some authorities consider coadministration of live, attenuated oral cholera vaccine with immunosuppressant therapies contraindicated. Administration of live attenuated vaccines in severely immunocompromised persons is generally considered a contraindication. The risks of adverse reactions or a decreased or suboptimal immunologic response should be weighed against the benefits of vaccination. Current local immunization guidelines and individual product labeling for the prescribed immunosuppressive therapy should be consulted for further information.
Drug and food interactions
cholera vaccine, live food
Applies to: Vaxchora (cholera vaccine, live)
Administration of cholera vaccine, live with food or drink may reduce its effectiveness. Avoid eating or drinking for 60 minutes before and after taking cholera vaccine, live.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Vyvgart Hytrulo
Vyvgart Hytrulo is used to treat generalized myasthenia gravis (gMG) or chronic inflammatory ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Enspryng
Enspryng is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Zilbrysq
Zilbrysq (zilucoplan) is a C5 inhibitor used to treat generalized myasthenia gravis (gMG) in AChR ...
Rystiggo
Rystiggo is used to treat generalized myasthenia gravis (gMG) in adults who are acetylcholine ...
Mestinon
Mestinon (pyridostigmine) is used to increase muscle strength in conditions such as myasthenia ...
Vyvgart
Vyvgart is used for myasthenia gravis to improve muscle weakness in adults whose myasthenia gravis ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.